In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
IC50: 79 nM for EphB3
LDN-211904 is an inhibitor of erythropoietin-producing hepatocellular carcinoma (Eph) receptors.
Erythropoietin-producing hepatocellular carcinoma (Eph) receptors, a group of highly conserved transmembrane proteins composed of multiple domains, participate in various cell signaling pathways. So far, 16 Eph receptors have been identified in vertebrates, which can be divided into two major classes (EphA and EphB) based on sequence similarity. Mammals including humans have 14 Eph receptors (EphA1–EphA8, EphA10, EphB1–EphB4 and EphB6).
In vitro: Previous study found that LDN-211904, a 4-piperidinyl analog, retained significant EphB3 inhibitory activity, and also had greater aqueous solubility due to the presence of a basic amine. LDN-211904 was profiled for functional inhibitory activity against a panel of 288 kinases and the results showed that LDN-211904 was quite selective for tyrosine kinases. The only noted exceptions were the three serine/threonine kinases p38a, p38b, and Qik. In addition, only LDN-211904 showed moderate selectivity among the tyrosine kinases and little selectivity verses other EphA and EphB subtypes, except for EphA6 and EphA7. Moreover, LDN-211904 demonstrated the best stability with a t1/2 of 348 min and a CLint of 4 μL/min/mg protein .
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
 Qiao, L. ,Choi, S.,Case, A., et al. Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors. Bioor. Med. Chem. Lett. 19(21), 6122-6126 (2009).
|Physical Appearance||A crystalline solid|
|Storage||Store at -20°C|
|Solubility||≤20mg/ml in DMSO;0.5mg/ml in dimethyl formamide|
|Chemical Name||N-(2-chlorophenyl)-6-(4-piperidinyl)-imidazo[1,2-a]pyridine-3-carboxamide, monoethanedioate|
|Shipping Condition||Ship with blue ice, or upon other requests.|
|General tips||For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon.|